2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
11
Lung Neoplasms
3
Glioblastoma
3
Cognitive Dysfunction
3
Breast Neoplasms
3
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Tobacco Use Disorder
1
Recurrence
1
Rectal Neoplasms
1
Peripheral Nervous System Diseases
1
Neurotoxicity Syndromes
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Motor Activity
1
Melanoma
1
Gliosarcoma
1
Gastrointestinal Neoplasms
1
Fibrosis
1
Epilepsy
1
Ependymoma
1
Craniopharyngioma
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Carcinoma
1
Carcinoma, Renal Cell
1
Interventions
Sirolimus
4
LY3295668 erbumine
3
Everolimus
3
Medical Marijuana
2
Anticonvulsants
2
ziprasidone
1
perampanel
1
enzalutamide
1
clevidipine
1
brivaracetam
1
Zolpidem
1
Warfarin
1
Vigabatrin
1
Vecuronium Bromide
1
Vancomycin
1
Tranexamic Acid
1
Topotecan
1
Tobramycin
1
Therapeutic Touch
1
Temozolomide
1
TAS-119
1
Surgical Procedures, Operative
1
Sulfasalazine
1
Spironolactone
1
Sevoflurane
1
Sevelamer
1
Saline Solution
1
Rocuronium
1
Registries
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Epilepsy
×
Memantine
×
Clear all
NCT05664464
2024-05-10
GLUGLIO
University of Zurich
Phase 1/2
Recruiting
120 enrolled